Deborah E Collyar
Overview
Explore the profile of Deborah E Collyar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
819
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Andre F, Ismaila N, Allison K, Barlow W, Collyar D, Damodaran S, et al.
J Clin Oncol
. 2022 Apr;
40(16):1816-1837.
PMID: 35439025
Purpose: To update recommendations on appropriate use of breast cancer biomarker assay results to guide adjuvant endocrine and chemotherapy decisions in early-stage breast cancer. Methods: An updated literature search identified...
2.
Rosenberg S, Gierisch J, Revette A, Lowenstein C, Frank E, Collyar D, et al.
Cancer
. 2022 Feb;
128(8):1676-1683.
PMID: 35191017
Background: Of the nearly 50,000 women in the United States who undergo treatment for ductal carcinoma in situ (DCIS) annually, many may not benefit from treatment. To better understand the...
3.
Jimenez R, Johnson A, Horick N, Hlubocky F, Lei Y, Matsen C, et al.
Cancer
. 2021 Oct;
128(2):275-283.
PMID: 34633655
Background: Audio recordings of oncology clinic discussions can help patients retain and understand information about their disease and treatment decisions. Access to this tool relies on acceptance of recordings by...
4.
Collyar D, Gautier L
Future Oncol
. 2021 Sep;
17(28):3663-3666.
PMID: 34505795
No abstract available.
5.
Collyar D
Cancer J
. 2020 Aug;
26(4):292-297.
PMID: 32732671
Modern medical costs fall beyond most peoples' ability to pay and cause severe adverse effects that impact patients and families. It is time to team up with all stakeholders to...
6.
Nunes A, Collyar D, Harris L
JNCI Cancer Spectr
. 2019 Jul;
1(1):pkx008.
PMID: 31360834
Biomarkers are frequently used to guide decisions for treatment of early-stage estrogen (ER) and progesterone (PR) receptor-positive (ER/PR+) invasive breast cancers and have been incorporated into guidelines. The American Society...
7.
Andre F, Ismaila N, Henry N, Somerfield M, Bast R, Barlow W, et al.
J Clin Oncol
. 2019 Jun;
37(22):1956-1964.
PMID: 31150316
Purpose: This focused update addresses the use of Onco DX in guiding decisions on the use of adjuvant systemic therapy. Methods: ASCO uses a signals approach to facilitate guideline updating....
8.
Krop I, Ismaila N, Andre F, Bast R, Barlow W, Collyar D, et al.
J Clin Oncol
. 2017 Jul;
35(24):2838-2847.
PMID: 28692382
Purpose This focused update addresses the use of MammaPrint (Agendia, Irvine, CA) to guide decisions on the use of adjuvant systemic therapy. Methods ASCO uses a signals approach to facilitate...
9.
Harris L, Ismaila N, McShane L, Andre F, Collyar D, Gonzalez-Angulo A, et al.
J Clin Oncol
. 2016 Feb;
34(10):1134-50.
PMID: 26858339
Purpose: To provide recommendations on appropriate use of breast tumor biomarker assay results to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer. Methods: A literature...
10.
Cottler L, McCloskey D, Aguilar-Gaxiola S, Bennett N, Strelnick H, Dwyer-White M, et al.
Am J Public Health
. 2013 Feb;
103(9):1685-92.
PMID: 23409875
Objectives: We used results generated from the first study of the National Institutes of Health Sentinel Network to understand health concerns and perceptions of research among underrepresented groups such as...